



PRODUCT: **ASPARLAS®**

COMPANY: Servier Pharmaceuticals

THERAPEUTIC AREA & INDICATION:

Component therapy of a multi-agent chemotherapy regimen for treatment of acute lymphoblastic leukemia (ALL) in patients 21 years of age or younger

ABOUT THE PRODUCT

ASPARLAS, a newer form of PEGylated asparaginase, is a component of multi-agent chemotherapeutic regimen to treat acute lymphoblastic leukemia (ALL) in pediatric and young adult patients. No chemotherapy drug has made a greater impact to patients with ALL than asparaginase. ASPARLAS decreases the dosing schedule for patients and improves the stability of the shelf life to 36-months. The extended shelf life allows for an improved supply chain allowing hospitals to ensure they always have ASPARLAS on hand when a patient is diagnosed or scheduled for treatment. In numerous clinical studies survival rates for patients with ALL are 34-53% higher when asparaginase is added to the standard ALL backbone treatment regimen.